Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectio...(ntigens licensed from its collaborative ...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
Date:7/1/2009
ntigens licensed from its collaborative partners.
About Morphotek
Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, is a biopharmaceutical company specializing in the development of protein and antibody products through the use of novel and proprietary technologies. These technologies have been successfully applied to a variety of molecules that are suitable for pharmaceutical product development in the areas of antibody therapeutics, protein therapeutics, product manufacturing, drug target discovery, and improved output traits for commercial applications. The company is currently focusing its platform on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation and infectious disease. For more information, please visit www.morphotek.com.
About Eisai Corporation of North America
Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd., and supports the activities of its operating companies in North America, which include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintains pharmaceutical manufacturing machinery.
About Synageva
Synageva BioPharma Corporation is a biopharmaceutical company dedicated to developing and commercializing novel, next generation, and follow-on protein therapeutics that leverage the unique competitive advantages of its proprietary Synageva Expression Platform (SEP(TM)). Synageva's development programs address specific unme
'/>"/>
| SOURCE Morphotek, Inc. Copyright©2009 PR Newswire. All rights reserved |
Related biology technology :
1. Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma
2. Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology
3. Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
(Date:11/30/2009)...OOMINGTON, Minn., Nov. 30 Acuo Tec...image management software, data migration tools an...a Hospitals and Clinics for a new Vendor Neutral A...orage across the Allina network of hospitals, clin...s based on the Acuo Technologies DICOM Services Gr...
(Date:11/30/2009)...OCKVILLE, Md., Nov. 30 N...cine company, announced today that the company wil...ference 2009 on December 2, 2009 at 12:30 pm local...ill provide an overview of the company,s business ...coming milestones. A link to the live audio only ...
(Date:11/30/2009)... AMSTERDAM, November 30 Biopharm...at the first patients have been enrolled in its,mu...TM). The study is,designed to show reduction in tr...llowing an allogeneic stem cell transplantation wi...ancer patients eligible for an allogeneic,stem cel...
(Date:11/30/2009)... CHANGCHUN, China and LOS ANGELES, Nov. 30 /PR...uticals, Inc. (OTC Bulletin Board: CYXN; ,China Yo...g manufacturer, distributor and,retailer of pharma...t has,completed preparation for distribution of me... Chinese government recently formalized the nation...
Breaking Biology Technology:Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 2Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 3NOVAVAX to Present at the Piper Jaffray 21st Annual Health Care Conference 2Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 3[0] Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics[0] NOVAVAX to Present at the Piper Jaffray 21st Annual Health Care Conference[0] Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM)[0] China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List
...affiliate of,Phlo Corporation (Pink Sheets: PHLC) ...ion of its vitality product, AQUISS(TM), in Califo... within Northern California and has,been introduce...with the,Palm Desert/Palm Springs area. In Northe...ndiser,Holiday Meeting, which was instrumental in ...
...se Review with Drs. Morton Kern, Nico ...en and WILMINGTON, Mass., Oct. 19 The use,of frac...utcomes is the,topic of several sessions at this y...mposium, TCT 2007, which will take place Oct. 20-2...st company to develop systems that,calculate FFR w...
...PRNewswire-FirstCall/ -- Simcere,Pharmaceutical Gr...lier of,branded generic pharmaceuticals in the rap...hat it intends to release its 2007 third quarter r...ket opens in the United States.,Simcere,s chief ex...,officer, Frank Zhigang Zhao, will host an earning...
Other Biology Technology:AQUISS Continues Expansion Into New Territory 2Use of Fractional Flow for Optimizing Patient Outcomes is Topic of Several Sessions at TCT 2007 2Simcere Pharmaceutical Group to Announce Third Quarter 2007 Earnings on Monday, November 5, 2007 2Simcere Pharmaceutical Group to Announce Third Quarter 2007 Earnings on Monday, November 5, 2007 3(Date:12/1/2009)...S, Ohio Ohio State University cancer researchers ...kills brain-tumor cells and blocks the growth of n...hat viruses designed to kill cancer cells oncolyt...sive brain tumors if they also carry a gene for a ...protein, called vasculostatin, is normally produce...
(Date:12/1/2009)..., NEW YORK, Dec. 1 iQor, a glob...services, was included in the 2009 InfoWorld 100...ic-enabled ERP system, TeQ21. This was the first s...cognized among this prestigious list of companies,...eQ21 is completely transforming the way we do busi...
(Date:12/1/2009)...ess, like a bad cold, can spread among groups of p...University of California-San Diego and Harvard sho...study that has been following health conditions fo...t lonely people tend to share their loneliness wit...disconnected people moves to the fringes of social...
Breaking Biology News(10 mins):Tumor-attacking virus strikes with 'one-two punch' 2iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2Loneliness can be contagious 2Loneliness can be contagious 3Amilpar Operating Revenues Grew 9 25 in the Second Quarter and 11 25 in the First Half of 2009 54276 1Amilpar Operating Revenues Grew 9 25 in the Second Quarter and 11 25 in the First Half of 2009 54276 2Fenwal and Golden Meditech Agree to Form Joint Venture in China for Blood Collection and Transfusion Technologies 13513 1Fenwal and Golden Meditech Agree to Form Joint Venture in China for Blood Collection and Transfusion Technologies 13513 2Fenwal and Golden Meditech Agree to Form Joint Venture in China for Blood Collection and Transfusion Technologies 13513 3Postdiagnosis aspirin use reduces risk of dying from colorectal cancer 54274 1Postdiagnosis aspirin use reduces risk of dying from colorectal cancer 54274 2...ity of North Carolina at Chapel Hill,s newest "lib...book lover, but it eventually will please thousand...ch researchers, work, it will undoubtedly contribu...t depend on every day, its developers say. , Named...oluminous genetic data on 39 plant species. The li...
... not for fun but for fuel. Burning grass for energ...r decades. But not in the United States. , Yet bur...rgy-efficient, environmentally friendly and sustai...t. , This alternative fuel easily could be produc...stoves built to burn wood pellets or corn, says Je...
...ns infectious disease specialists who have spent m... and AIDS worldwide are warning that limited inter...es currently being distributed in Africa, Asia and... afford to pay for them. , In an article appearing...une 28, infectious disease specialist Jonathan Zen...
Other Biology News:Unique library of plant genes germinates, takes root at UNC 2Grass makes environmentally friendly biofuel 2Hopkins AIDS experts issue warning about global efforts to provide drug therapies 2Hopkins AIDS experts issue warning about global efforts to provide drug therapies 3Hopkins AIDS experts issue warning about global efforts to provide drug therapies 4Goat Anti-HIV-1 HIV1 p24 Antibody, Unconjugated from ABR-Affinity BioReagents
Anti-Human CD11b / Mac-1alpha Monoclonal Antibody, Unconjugated, Clone LM2 / 1 from Cell Sciences
RABBIT (BABY) COMPLEMENT LYOPHILISED from AbD Serotec
Rabbit Anti-Human ZO-1 Antibody, Unconjugated from Lab Vision
Biology Products:| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |